<DOC>
	<DOCNO>NCT01496534</DOCNO>
	<brief_summary>This phase Ib dose escalation study dovitinib give combination either gemcitabine plus cisplatin carboplatin patient advance solid tumor . Patients advance solid tumor , treatment gemcitabine plus cisplatin carboplatin would otherwise warrant , enrol . The dose dovitinib escalate successive cohort use standard `` 3+3 '' dose escalation rule . Patients continue treatment , absence prohibitive toxicity , disease progression . The study define recommend phase II dose combination regimen .</brief_summary>
	<brief_title>Phase Ib Study Gemcitabine Plus Cisplatin Carboplatin Plus Dovitinib Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This phase Ib study dovitinib give combination gemcitabine plus cisplatin carboplatin patient advance solid tumor . This study utilize standard 3+3 dose escalation rule define recommend phase II dose . Dose escalation proceed independently two cohort ( cisplatin cohort : gemcitabine + cisplatin + dovitinib ; carboplatin cohort : gemcitabine + carboplatin + dovitinib ) . Patients receive treatment 6 cycle , absence toxicity , disease progression Primary Objective : To determine recommended phase II dose dovitinib give combination gemcitabine plus cisplatin carboplatin . Secondary Objectives : - To determine response rate treatment per Response Evaluation Criteria Solid Tumors ( RECIST ) - To determine toxicity treatment per Common Terminology Adverse Events ( CTCAE v4 ) - To determine pharmacokinetics dovitinib combination gemcitabine plus cisplatin carboplatin .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Written inform consent HIPAA authorization release personal health information . Age ≥ 18 year time consent . Karnofsky Performance Status ≥ 70 % . Advanced/metastatic solid tumor treatment gemcitabine plus carboplatin gemcitabine plus cisplatin would otherwise warrant . Prior treatment chemotherapy permit . Patients must receive three prior chemotherapeutic regimen . Adequate organ function determine follow laboratory value : Hemoglobin ( Hgb ) ≥ 9 g/dL Platelets ≥ 100 x 109/L Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Creatinine ≤ 1.5 OR Calculated creatinine clearance ≥ 60 cc/min cisplatin cohort . Calculated creatinine clearance ≥ 30 cc/min carboplatin cohort . Bilirubin ≤ 1.5 x ULN Aspartate aminotransferase ( AST , SGOT ) ≤ 1.5 ULN Alanine Aminotransferase ( ALT , SGPT ) &lt; 1.5 ULN INR ≤ 1.5 PTT within normal limit LVEF assess 2D echocardiogram ( ECHO ) &gt; 50 % low limit normal multiple gated acquisition scan ( MUGA ) &gt; 45 % low limit normal Prior treatment three prior chemotherapy regimen . Has major surgery within 30 day start study treatment Have active CNS metastasis . No treatment investigational agent within 30 day prior register protocol therapy . Prior cancer treatment must complete least 30 day prior register protocol therapy subject must recover acute toxic effect regimen . Prior radiation therapy must complete least 30 day prior register protocol therapy . Pregnant breastfeeding . Clinically significant infection judge treat investigator . Impaired cardiac function clinically significant cardiac disease Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption dovitinib ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) Patients currently receive anticoagulation treatment therapeutic dos warfarin Women childbearing potential , biologically able conceive , employ two form highly effective contraception . Fertile male willing use contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>carboplatin</keyword>
	<keyword>solid tumor</keyword>
</DOC>